Within the consortium 4 clinical research centers of excellence with long-standing experience in performing and coordinating multi-centered randomized controlled clinical trials are entrusted with the clinical part of the project.
BM4SIT is supported by academic partners with outstanding expertise in molecular biology, proteomics, protein chemistry and immunochemistry of allergenic molecules and derivatives. Immunoassay development, quality control of the drug substance and drug product for BM4SIT, and the control of serological and cellular immune responses during the clinical trials will be performed by these partner organizations.
The consortium is distributed over 6 countries; Austria, Denmark, Finland, Germany, The Netherlands, and Poland. The composition of the consortium has been guided by the geographic spread of birch pollen allergy showing a distinct hotspot in Central and North-Western Europe.